Abstract:Objective: To provide a brief overview of the clinical presentation, common offending agents, management, prognosis, and mortality of 6 selected high-risk drug rashes, namely, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, multiple drug hypersensitivity (MDH) syndrome, acute generalized exanthematous pustulosis (AGEP), and drug-induced bullous pemphigoid (DIBP). Data sources: A review of the published literature was performed with PubMed and supplemented with our clinical experience. Study selections: The most recent clinically relevant studies and older seminal works were selected. Results: Most of the published data on these uncommon rashes were based on small observational series or case reports. SJS and TEN have specific genotypes association with certain drugs, have high morbidity and mortality, and require aggressive management by a team of multiple specialists. DRESS syndrome is a severe, prolonged multiorgan reaction, yet it has a better prognosis than TEN. MDH is a syndrome of repeated reactions to unrelated drugs that often imposes diagnostic and management difficulties. AGEP consists of generalized sterile small pustules, usually mistaken for infection with subsequent inappropriate treatment. Bullous pemphigoid presents with tense pruritic bullae and characteristic linear basement membrane deposition of IgG and C3. DIBP has much better prognosis than the autoimmune variety. Conclusion: In such high-risk drug rashes, early recognition, immediate withdrawal of the suspected drug(s), prompt individualized management, and monitoring of vital organs function are mandatory for reducing morbidity and mortality. The lack of reliable tests for identification of the causative agent imposes difficulty, particularly in patients receiving multiple medications.

Advanced Studies on the Pathogenesis of Drug Eruption

Drug-induced Exfoliative Dermatitis: Literature Analysis of 240 Cases

Drug-induced Erythroderma in Patients with Acquired Immunodeficiency Syndrome.

Update of etiology and risk factors of toxic epidermal necrolysis

Association Between Serum Ferritin and the Severity of Drug Eruptions

Purulent Bullous Epidermal Necrolysis: A Potential New Clinical Pattern of Drug Eruption

Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans

Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions

Recent progress of Stevens-Johnson syndrome/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy

Research progress of epidermolysis bullosa eruption

028 Comprehensive Assessment of T Cell Receptor Β Repertoire in Stevens–Johnson Syndrome/toxic Epidermal Necrolysis Patients Using High-Throughput Sequencing

High-risk drug rashes

Animal models of toxic epidermal necrolysis

Histopathological study of six types of adverse cutaneous drug reactions using granulysin expression

Analysis of 101 Epidermolysis Bullosa Type Eruption Cases

Annular drug eruptions

Cutaneous allergic drug reactions: update on pathophysiology, diagnostic procedures and differential diagnosic

Toxic Epidermal Necrolysis with Systemic Lupus Erythematosus: Case Report and Review of the Literature

Toxic Epidermal Necrolysis Caused by Viral Hepatitis A: a Case Report and Literature Review

Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis – diagnosis and treatment